Neal Flomenberg Sells 70,384 Shares of Tevogen Bio Holdings Inc. (NASDAQ:TVGN) Stock

Tevogen Bio Holdings Inc. (NASDAQ:TVGN) insider Neal Flomenberg sold 70,384 shares of the firm’s stock in a transaction that occurred on Monday, March 10th. The shares were sold at an average price of $1.09, for a total transaction of $76,718.56. Following the transaction, the insider now directly owns 3,898,828 shares in the company, valued at approximately $4,249,722.52. The trade was a 1.77 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website.

Neal Flomenberg also recently made the following trade(s):

• On Thursday, March 6th, Neal Flomenberg sold 88,519 shares of Tevogen Bio stock. The shares were sold at an average price of $1.10, for a total transaction of $97,370.90.
• On Tuesday, March 4th, Neal Flomenberg sold 14,639 shares of Tevogen Bio stock. The shares were sold at an average price of $1.28, for a total transaction of $18,737.92.

Tevogen Bio Stock Up 3.7 %

Shares of TVGN opened at $1.11 on Thursday. The firm’s 50 day moving average price is $1.36 and its 200 day moving average price is $1.17. Tevogen Bio Holdings Inc. has a twelve month low of $0.26 and a twelve month high of $6.53.

Hedge Funds Weigh In On Tevogen Bio

A number of institutional investors have recently modified their holdings of TVGN. HGC Investment Management Inc. bought a new position in shares of Tevogen Bio in the third quarter valued at approximately $82,000. China Universal Asset Management Co. Ltd. bought a new position in shares of Tevogen Bio in the fourth quarter valued at approximately $38,000. JPMorgan Chase & Co. raised its position in shares of Tevogen Bio by 74.2% in the fourth quarter. JPMorgan Chase & Co. now owns 39,207 shares of the company’s stock valued at $40,000 after purchasing an additional 16,695 shares during the period. Geode Capital Management LLC raised its position in shares of Tevogen Bio by 31.2% in the fourth quarter. Geode Capital Management LLC now owns 451,851 shares of the company’s stock valued at $465,000 after purchasing an additional 107,566 shares during the period. Finally, Barclays PLC raised its position in shares of Tevogen Bio by 39.2% in the fourth quarter. Barclays PLC now owns 45,600 shares of the company’s stock valued at $48,000 after purchasing an additional 12,847 shares during the period.

Analyst Ratings Changes

Separately, D. Boral Capital reaffirmed a “buy” rating and set a $10.00 price objective on shares of Tevogen Bio in a research report on Tuesday.

Tevogen Bio Company Profile

Tevogen Bio Holdings Inc operates as a clinical-stage specialty immunotherapy company that develops off-the-shelf precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders. The company develops TVGN 489, which has completed Phase 1 clinical trial for the treatment and prevention of chronic lingering symptoms of the disease (Long COVID), as well as COVID-19 in B cell immune suppressed acute COVID-19 patients without a B cell cancer indication, elderly and infirm acute COVID-19 patients, and acute COVID-19 in patients on T cell suppressing drugs, including solid organ transplant patients.